AUG 07, 2018 11:00 PM PDT

Can a Myeloid Marker Be Helpful in B-cell Neoplasm Diagnostic Testing?

Diagnostic testing for hematologic and other cancers has been a traditional method of evaluating, diagnosing, and providing prognostic information to providers choosing treatment and options for oncology patients.  Molecular diagnostics, in particular, have jumped to the forefront of diagnostic testing to provide not only a diagnosis, but to also evaluate the biomarkers present in particular groups of cells; biomarker identification predicts disease behavior, helps in selection of therapeutic treatment targets and options, assists in stratification of disease, and provides a personalized medicine approach. 

Immunophenotyping has become an invaluable diagnostic tool used by clinicians and hematopathologists to fit cancers into appropriate subgroups based on the biomarkers present on tumor involved cell lines. 

There are a multitude of B-cell neoplasms including multiple myeloma, chronic lymphocytic leukemia, small lymphocytic leukemia, diffuse large B-cell lymphoma, follicular lymphoma, Burkitt’s lymphoma, Mantle cell lymphoma, and others.  In these cases, because they are lymphoid in origin, it is unexpected to find myeloid markers, however, researchers at Stanford and Oregon Health Sciences in Portland found that CD13, a myeloid marker, is expressed in a subset of lymphomas which can be helpful in differentiating between B-cell neoplasms in the clinical setting.

The group published their findings in the International Journal of Laboratory Hematology, which outlined their analysis of 286 mature B-cell neoplasms after immunophenotyping was completed.  CD13 expression was found in cases of lymphoplasmacytic lymphoma (LPL) (61.5% of cases) and FMC7-positive chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) (37% of cases).  Notably, there were no cases of follicular lymphoma that expressed CD13. 

The group concluded that CD13 expression is usually present in LPL and FMC7-positive CLL or SLL and is not found in FL.  Historically, CD13 has not been used to characterize B-cell neoplasm subtypes but could be a useful diagnostic means to aid in neoplasm subtyping and furthering B-cell neoplasm therapeutic targeting.

Sources: International Journal of Laboratory Hematology, Archives of Pathology & Laboratory Medicine, Clinics in Oncology , Modern Pathology 

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
JUN 07, 2018
Clinical & Molecular DX
JUN 07, 2018
Digital Screening Vital for Detecting Breast Cancer
A combination of two digital techniques could be the best way to diagnose breast cancer. In a new study, scientists show how combining a technique called t...
JUN 12, 2018
Cancer
JUN 12, 2018
CD44 Insights & Cancer Influence
CD44 is a known cell surface protein involved in numerous interactions; it is overexpressed in cancerous tissue and its isoforms are being investigated as targets for cancer immunotherapy...
JUN 19, 2018
Cancer
JUN 19, 2018
Cancer-Related Cognitive Impairment aka "ChemoBrain" Needs YOU!
There is a need for neuroscientists to investigate what is known as chemobrain; survivors and providers are looking for ideas for approaches to mitigating this late effect chemo related issue...
JUL 17, 2018
Cancer
JUL 17, 2018
Immunotherapy Diversification: From CAR-T cells to CAR-NK cells
New advances have made it possible for immunotherapy researchers to use natural killer cells, which are our body's normal defense for cancerous cells, to target tumors....
OCT 04, 2018
Videos
OCT 04, 2018
Zebrafish as Metastatic Cancer Model
Another Koch Institute Image Award winner from 2018 is presented in this video from MIT....
OCT 06, 2018
Genetics & Genomics
OCT 06, 2018
Genetic Mutation Linked to Increased Pancreatic Cancer Risk in Women
In a first, researchers have found a genetic mutation that has a sex-specific effect on pancreatic cancer risk....
Loading Comments...